Masahito Nakano

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4011798/publications.pdf

Version: 2024-02-01

33	693	516710 16	580821 25
papers	citations	h-index	g-index

35	35	35	1005
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis. Molecular and Clinical Oncology, 2014, 2, 393-398.	1.0	64
2	Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Cancers, 2020, 12, 1867.	3.7	56
3	Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Cancer Medicine, 2015, 4, 1836-1843.	2.8	54
4	Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers, 2021, 13, 2786.	3.7	44
5	Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decisionâ€tree analysis after propensity score matching. Hepatology Research, 2019, 49, 919-928.	3.4	42
6	Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events. Cancers, 2020, 12, 1010.	3.7	42
7	Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatology International, 2019, 13, 293-301.	4.2	38
8	Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study. Cancers, 2021, 13, 160.	3.7	38
9	Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma. Oncology, 2013, 84, 108-114.	1.9	31
10	Clinical effects and safety of intraâ€‘arterial infusion therapy of cisplatin suspension in lipiodol combined with 5â€‘fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extraâ€‘hepatic spread: A prospective cohort study. Molecular and Clinical Oncology, 2017, 7, 1013-1020.	1.0	27
11	Predictors of hepatocellular carcinoma recurrence associated with the use of directâ€acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study. Cancer Medicine, 2019, 8, 2646-2653.	2.8	27
12	Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study. Nutrients, 2020, 12, 1076.	4.1	27
13	Serum albumin level is a notable profiling factor for nonâ€<scp>B</scp>, nonâ€<scp>C</scp> hepatitis virusâ€related hepatocellular carcinoma: A dataâ€mining analysis. Hepatology Research, 2014, 44, 837-845.	3.4	26
14	Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2016, 77, 243-250.	2.3	21
15	High serum interleukinâ€34 level is a predictor of poor prognosis in patients with nonâ€viral hepatocellular carcinoma. Hepatology Research, 2019, 49, 1046-1053.	3.4	21
16	Primary Treatment with Molecularâ€Targeted Agents for Hepatocellular Carcinoma: A Propensity Scoreâ€matching Analysis. Hepatology Communications, 2020, 4, 1218-1228.	4.3	21
17	Survival Benefit of Hepatic Arterial Infusion Chemotherapy over Sorafenib in the Treatment of Locally Progressed Hepatocellular Carcinoma. Cancers, 2021, 13, 646.	3.7	19
18	Firstâ€line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Medicine, 2021, 10, 8530-8541.	2.8	12

#	Article	IF	Citations
19	Hepatic Arterial Infusion Chemotherapy with Cisplatin versus Sorafenib for Intrahepatic Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. Cancers, 2021, 13, 5282.	3.7	11
20	Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Scientific Reports, 2022, 12, 1517.	3.3	10
21	Recent progress in the management of hepatocellular carcinoma detected during a surveillance program in Japan. Hepatology Research, 2010, 40, 989-996.	3.4	9
22	Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma. Oncology, 2019, 96, 79-86.	1.9	9
23	Prevalence and profiles of ramucirumabâ€'associated severe ascites in patients with hepatocellular carcinoma. Molecular and Clinical Oncology, 2021, 14, 79.	1.0	8
24	Therapeutic Outcomes and Prognostic Factors of Unresectable Intrahepatic Cholangiocarcinoma: A Data Mining Analysis. Journal of Clinical Medicine, 2021, 10, 987.	2.4	7
25	Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrastâ€enhanced ultrasound. Cancer Reports, 2022, 5, e1471.	1.4	7
26	Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy. Oncology, 2019, 96, 192-199.	1.9	4
27	Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival. Oncology, 2021, 99, 756-765.	1.9	4
28	Usefulness of a novel transarterial chemoinfusion plus externalâ€beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study. Cancer Reports, 2022, 5, e1539.	1.4	3
29	Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study. Oncotarget, 2016, 7, 64400-64409.	1.8	3
30	Hepatitis C Virus Elimination Using Direct Acting Antivirals after the Radical Cure of Hepatocellular Carcinoma Suppresses the Recurrence of the Cancer. Cancers, 2022, 14, 2295.	3.7	3
31	Durable complete response is achieved by balloonâ€occluded transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatology Communications, 2022, 6, 2594-2604.	4.3	3
32	Association between contrast enhancement on contrastâ€'enhanced CT and lenvatinib effectiveness in hepatocellular carcinoma. Molecular and Clinical Oncology, 2021, 16, 8.	1.0	2
33	Percutaneous Radiofrequency Ablation with or without Chemolipiodolization for Hepatocellular Carcinoma: A Propensity-Score-Matched Analysis. Journal of Clinical Medicine, 2022, 11, 1483.	2.4	0